NCT06162013View on ClinicalTrials.gov

The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism

PHASE2RecruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Progressive Supranuclear PalsyMultiple System AtrophyCorticobasal Syndrome
Interventions
DIETARY_SUPPLEMENT

Nicotinamide Riboside

Nicotinamide Riboside 3000mg/day

OTHER

Placebo

Placebo. Identical in taste and appearance as the intervention.

Trial Locations (3)

5021

RECRUITING

Haukeland University Hospital, Bergen

0424

RECRUITING

Oslo University Hospital, Oslo

Unknown

RECRUITING

Vestre Viken HF, Drammen

Sponsors

Collaborators (1)

Elysium Health
All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

collaborator

Akershus Universitetssykehus HF

UNKNOWN

collaborator

Vestre Viken Hospital Trust

OTHER

collaborator

Sykehuset Ostfold

OTHER

collaborator

Nevro Arendal AS

UNKNOWN

collaborator

Helse Forde

OTHER

collaborator

Helse Fonna

OTHER

collaborator

Universitetssykehuset Nord Norge HF

UNKNOWN

collaborator

Helse Møre og Romsdal HF

OTHER_GOV

collaborator

Nordlandssykehuset HF

OTHER

collaborator

Elysium Health

INDUSTRY

lead

Haukeland University Hospital

OTHER

NCT06162013 - The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism | Biotech Hunter | Biotech Hunter